Some insurers have raised concerns regarding the impact of expected tariffs on insurance prices, as detailed in legal filings with regulators. A document from United Healthcare of New York indicates that due to uncertainties surrounding tariffs and the potential onshoring of manufacturing, a total price impact of 3.6% has been incorporated into their initial rate filings, reflecting the anticipated effect on medical costs, particularly for pharmaceuticals.
While these tariffs and the rising costs of obesity medications are contributing to an increase in overall healthcare expenses, a more pressing issue is the fate of extra subsidies for approximately 24 million individuals enrolled in Affordable Care Act (ACA) plans. If these subsidies are discontinued, many could see their premium payments effectively double by January. Notably, around half of the adults benefitting from these subsidies are either small-business owners, their employees, or self-employed individuals, according to data from the Kaiser Family Foundation (KFF).
Initially introduced during the coronavirus pandemic to enhance affordability for HealthCare.gov coverage, these subsidies have remained in place for five years. Their implementation has led to a significant increase in ACA enrollment, doubling the number of participants to over 24 million and effectively reducing the uninsured rate in the nation. However, the provision of these subsidies has resulted in substantial costs for taxpayers, with estimates indicating that an additional ten-year extension would amount to $335 billion, as per the Congressional Budget Office (CBO).
Congress has previously approved these subsidies on two occasions, yet with the current GOP-controlled House and Senate, it appears that they may allow the subsidies to expire after December. This follows their refusal to extend them in the recent tax and spending legislation passed during the summer.
The consequences of discontinuing the subsidies could be severe, with the CBO projecting that around 4 million individuals would abandon their ACA plans within the first year following their removal. This mass withdrawal would likely lead to a concentration of sicker, more expensive patients remaining in the insurance marketplaces, prompting insurers to respond with even higher premiums in the future.
